Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 11

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 11
---
 and
delivering results. Our delivery of significant stock price appreciation, strong execution, and operational successes demonstrate that we have the right leadership team and strategic vision in place. Maintaining this momentum is critical to
Zevra’s continued transformation into a leading rare disease company and to our continued efforts in delivering sustained value for you, our valued stockholders.

Whether or not you plan to attend the Annual Meeting, you have an opportunity to protect your investment in Zevra by voting theWHITE proxy
card. Your vote is extremely important, no matter how many or how few shares you own. We urge you to vote today, either online or by signing and dating the enclosedWHITE proxy card and returning it in the postage-paid
envelope provided. The Board strongly urges you to discard and not to sign or return any blue proxy card sent to you by Mr. Mangless.

This is an
important moment for Zevra’s future, and we hope we can count on your support. For all of the reasons we have outlined, we encourage you to vote on theWHITE proxy card “FOR” the re-election of Wendy Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board as Class I directors to hold office until the 2028 Annual Meeting of Stockholders.

We are excited about the opportunities ahead for Zevra. Thank you for your continued support.

Sincerely,

The Zevra Board of Directors

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.
is a commercial-stage company combining science, data, and patient need to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare
diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.

For more information, please visit or follow us on X and LinkedIn.

Cautionary Note Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s actions to enhance stockholder value, the Company’s plans with respect to director
candidates nominated by stockholders; the Company’s strategic, financial, operational, and product development objectives; and the timing of any of the foregoing. Forward-looking statements are based on